Scholarlink

Purpose <p>To improve clinical decision-making in patients with breast cancer receiving CDK 4/6 inhibitors, we examined Duffy status and relative medication modification at Boston Medical Center.</p> Methods <p>We performed a retrospective chart review of patients with breast cancer receiving CDK 4/6 inhibitors at Boston Medical Center between January 1, 2021 and June 1, 2024. We included Duffy status as a covariate, where those with unknown Duffy status were assumed to be Duffy non-null.</p> Results <p>Of the 71 patients included, race was White in 21% and Black in 54%, where 90% of patients with Duffy-null associated neutrophil count (DANC) were Black. When stratifying by Duffy status, Duffy non-null (38/71) and null patients (21/71) had median pre-treatment nadir absolute neutrophil count (ANC) 2.6 (IQR 1.8) and 1.7 (IQR 1.0) and post-treatment nadir ANC 1.6 (IQR 1.2) and 1.0 (IQR 0.6). Overall, no patients meeting criteria for grades 3–4 neutropenia were hospitalized for neutropenic fever. Older patients had higher odds of dose reduction or treatment delay (adjusted odds ratio [aOR] 3.04, 95% confidence interval [CI] 1.06–9.07). However, patients with DANC had no significant differences in rates of dose reduction or treatment delay [aOR 1.31, 95% confidence interval (CI) 0.37–4.73].</p> Conclusion <p>Despite having lower ANC than their non-null counterparts, Duffy null patients on CDK 4/6 inhibitors received standard starting doses without significant differences in dose reduction or treatment delay.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors

  • 期刊论文

  • 发表日期：

    2025年12月12日

查看全文
  • Grace M. Ferri,
  • Corina Beiner Martinez,
  • Jose Acevedo,
  • Sita Bhatt,
  • Karina P. Verma,
  • Jungwun Lee,
  • Maya Abdallah,
  • Raphael E. Szalat,
  • J. Mark Sloan

摘要

Purpose

To improve clinical decision-making in patients with breast cancer receiving CDK 4/6 inhibitors, we examined Duffy status and relative medication modification at Boston Medical Center.

Methods

We performed a retrospective chart review of patients with breast cancer receiving CDK 4/6 inhibitors at Boston Medical Center between January 1, 2021 and June 1, 2024. We included Duffy status as a covariate, where those with unknown Duffy status were assumed to be Duffy non-null.

Results

Of the 71 patients included, race was White in 21% and Black in 54%, where 90% of patients with Duffy-null associated neutrophil count (DANC) were Black. When stratifying by Duffy status, Duffy non-null (38/71) and null patients (21/71) had median pre-treatment nadir absolute neutrophil count (ANC) 2.6 (IQR 1.8) and 1.7 (IQR 1.0) and post-treatment nadir ANC 1.6 (IQR 1.2) and 1.0 (IQR 0.6). Overall, no patients meeting criteria for grades 3–4 neutropenia were hospitalized for neutropenic fever. Older patients had higher odds of dose reduction or treatment delay (adjusted odds ratio [aOR] 3.04, 95% confidence interval [CI] 1.06–9.07). However, patients with DANC had no significant differences in rates of dose reduction or treatment delay [aOR 1.31, 95% confidence interval (CI) 0.37–4.73].

Conclusion

Despite having lower ANC than their non-null counterparts, Duffy null patients on CDK 4/6 inhibitors received standard starting doses without significant differences in dose reduction or treatment delay.